

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN INSTITUTIONAL LLC,
Petitioner,

v.

NOVO NORDISK A/S,
Patent Owner.

Case IPR2020-00324
Patent 8,114,833

PATENT OWNER'S POWER OF ATTORNEY

PATENT OWNER'S POWER OF ATTORNEY

Patent Owner, Novo Nordisk A/S, hereby appoints the following as its attorneys to transact all business in the United States Patent & Trademark Office associated with the above-captioned *inter partes* review:

Jeffrey J. Oelke having a postal, email, and hand-delivery address of:

Jeffrey J. Oelke, Reg. No. 37,409
Fenwick & West LLP
902 Broadway, Suite 14
New York, New York 10010
Telephone: (212) 430-2600
joelke@fenwick.com

Ryan P. Johnson (*pro hac vice* to be sought), having a postal, email, and hand-delivery address of:

Ryan P. Johnson
Fenwick & West LLP
902 Broadway, Suite 14
New York, New York 10010
Telephone: (212) 430-2600
ryan.johnson@fenwick.com


Laura T. Moran (*pro hac vice* to be sought), having a postal, email, and hand-delivery address of:

Laura T. Moran
Fenwick & West LLP
902 Broadway, Suite 14
New York, New York 10010

Telephone: (212) 430-2600
laura.moran@fenwick.com

and all other practitioners working in conjunction with the aforementioned attorneys.

The individual signing below has the authority to execute this document on behalf of Novo Nordisk A/S.


[SIGNATURE]

Kamilla Winther
[BY]

Vice - President
[TITLE]

8 Jan 2020
[DATE]

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6 and 42.105, I hereby certify that the foregoing Patent Owner's Power of Attorney document was served on **January 9, 2020**, by filing this document through the Patent Trial and Appeal Board End to End System, as well as delivering a copy via electronic mail upon the following attorneys of record for the Petitioner:

Brandon M. White
Lara Dueppen
Perkins Coie LLP
white-ptab@perkinscoie.com
dueppen-ptab@perkinscoie.com

Date: January 9, 2020

Respectfully submitted,

/Jeffrey J. Oelke/
Jeffrey J. Oelke (Reg. No. 37,409)

Counsel for Novo Nordisk A/S